What the changes say
- New filing emphasizes manufacturing, healthcare-law, government-pricing, reimbursement, AI, geopolitical and tariff risks, plus cash obligations on the Notes.
- Cortrophin Gel generated a significant share of 2025 revenue; customer concentration narrowed to three customers, representing 64% of receivables.
- Merger-specific Alimera, unapproved-product, Medicare Coverage Gap and ownership risks were removed or folded into broader risks.
What changed since the prior 10-K
New
- NewRisks Related to our Business
Our manufacturing facilities or those of our third-party manufacturers or suppliers may fail to meet regulatory requirements. Failure to meet cGMP requirements could increase production costs or impact supply of our products
Manufacturing or supplier cGMP failures, including equipment, materials, quality systems or staffing problems, could disrupt supply and raise costs.
- NewRisks Related to our Business
If we fail to comply with broad and complex U.S. healthcare and other laws, as well as comparable laws and regulations in foreign jurisdictions, we could face substantial penalties and our business, operations and financial condition could be adversely affected
Violations of broad U.S. and foreign healthcare, fraud-and-abuse, privacy and related laws could trigger penalties, exclusion and operational restrictions.
- NewRisks Related to our Business
The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage, and security requirements intended to prevent the unauthorized sale of pharmaceutical products
Pharmaceutical distribution must meet extensive record-keeping, licensing, storage and security requirements intended to prevent unauthorized sales.
- NewRisks Related to our Business
Any failure to comply with the complex reporting and payment obligations under the Medicaid Drug Rebate Program and other government pricing and price reporting programs may result in penalties and sanctions, which may have a material adverse effect on our business, financial position, and operating results
Errors in Medicaid rebates or other government pricing reports could increase liabilities, penalties or jeopardize Medicare and Medicaid reimbursement.
- NewRisks Related to our Business
Any significant adverse events or undesirable side effects caused by our products may impact regulatory approval or market acceptance, or result in significant negative consequences
Product side effects could interrupt trials, add warnings, trigger lawsuits, damage reputation or cause approvals and market acceptance to be lost.
- NewRisks Related to our Business
Our current and potential future use of artificial intelligence and machine learning may not be successful and introduces emerging risks and challenges to our business
ANI’s expanding AI use could produce flawed outputs, privacy or compliance violations, intellectual-property problems and more automated cyberattacks.
- NewRisks Related to Our Industry
Any prolonged disruption in the supply of imported API or increased costs due to tariffs could materially affect our ability to manufacture and distribute our products, reduce or eliminate our revenues, and have a material adverse effect on our business, financial position, and operating results
The heading cites imported API and tariffs, but the supplied text instead describes safety-labeling risks for EEMT, Opium Tincture, Thyroid Tablets and Hyoscyamine.
- NewRisks Related to Our Industry
The successful commercialization of our products depends on adequate coverage and reimbursement from third party payors
Government and private payors may deny coverage, restrict utilization or reimburse too little for products to earn adequate returns.
- NewRisks Related to Our Industry
U.S. healthcare reform initiatives may materially and adversely affect our business and operating results
Federal and state healthcare reforms, including the Inflation Reduction Act, may make pharmaceutical commercialization, pricing and reimbursement more difficult.
- NewRisks Related to Our Industry
Other federal healthcare reform efforts or actions may affect access to healthcare coverage or the funding of health care benefits, although the full impact of such efforts or actions cannot be predicted
State pricing boards, supplemental Medicaid rebates, importation and bulk-purchasing initiatives could reduce coverage or reimbursement for ANI’s products.
- NewRisks Related to Accounting, Tax, and SEC Rules and Regulations
Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operations
Political, trade and regulatory changes, including threatened or retaliatory tariffs, could disrupt operations and damage financial results.
- NewRisks Related to our Debt
We may be unable to raise the funds necessary to repurchase the Notes for cash following a fundamental change or to pay the cash amounts due upon maturity or conversion of the Notes, and our other indebtedness limits our ability to repurchase the Notes or to pay the cash amounts due upon their maturity or conversion
ANI may lack cash or financing to repurchase or settle its Notes, while the 2024 Credit Agreement may restrict those payments.
Dropped
- DroppedRisks Related to our Business
We are subject to United States federal and state laws related to healthcare fraud and abuse and health information privacy and security, and the failure to comply with such laws may adversely affect our business
- DroppedRisks Related to our Business
Our accruals for the Medicare Coverage Gap Discount Program have increased due to growth and acquisitions. Any such change could have a material adverse effect on our business, financial position, and operating results
- DroppedRisks Related to Our Intellectual Property
We may fail to realize the benefits expected from our acquisition of Alimera and the combined company may not perform as we or the market expects, which could have an adverse effect on the price of our common stock
- DroppedRisks Related to Our Intellectual Property
The obligations and liabilities of Alimera, some of which may be unanticipated or unknown, may be greater than we have anticipated, which may diminish the value of Alimera us
- DroppedRisks Related to Our Intellectual Property
We have incurred, and will continue to incur, direct and indirect costs as a result of the Merger
Federal and state healthcare fraud, abuse, patient-rights and health-information privacy compliance.
- DroppedRisks Related to Our Intellectual Property
In connection with the Merger, we recorded goodwill and intangible assets and if either goodwill or intangible assets become impaired, our earnings could be significantly impacted
- DroppedRisks Related to Our Intellectual Property
The Merger may become the target of derivative lawsuits that could result in substantial costs in connection with the Merger
- DroppedRisks Related to our Industry
Four products, Esterified Estrogen with Methyltestosterone (“EEMT”), Opium Tincture, Thyroid Tablets, and Hyoscyamine are marketed without approved NDAs or ANDAs
Higher Medicare Coverage Gap rebate accruals caused by growth and acquisitions.
- DroppedRisks Related to our Industry
If third-party payers deny coverage, substitute another company’s product for our product, or offer inadequate levels of reimbursement, we may not be able to market our products effectively or we may be required to offer our products at prices lower than anticipated
- DroppedRisks Related to our Industry
Healthcare reform and changes in pharmaceutical pricing, reimbursement and coverage, by governmental authorities and third-party payors may materially affect our business, financial position and operating results
- DroppedRisks Related to our Common Stock
Our principal stockholders, directors, and executive officers own a significant percentage of our stock and will be able to exercise meaningful influence over our business
Reworded
- 74% rewrittenRisks Related to our Debt
Shares of our common stock issuable upon conversion of the Notes may dilute the ownership interest of our common stockholders or may adversely affect the market price of our common stock
The risk now refers to the Notes rather than Senior Notes; the potential dilution and stock-price effects are otherwise unchanged.
Was: Shares of our common stock issuable upon conversion of the Senior Notes may dilute the ownership interest of our common stockholders or may adversely affect the market price of our common stock
- 71% rewrittenRisks Related to our Business
Failure to successfully manage these risks in the implementation or acquisition of new lines of business or the offering of new products or services could have a material adverse effect on our reputation, business, results of operations and financial condition
Supplier exposure increased: one domestic supplier represented 17% of 2025 raw-material and API purchases versus 12% of API purchases in 2024.
- 71% rewrittenRisks Related to our Business
To the extent our ongoing and continuing efforts to commercialize Cortrophin Gel, ILUVIEN, and our other products for which we have received marketing approval are unsuccessful, our business, financial condition and results of operations will be negatively impacted
The discussion now emphasizes Cortrophin Gel’s significant share of 2025 revenue and expected future importance, rather than launch history and indications.
Was: Cortrophin Gel is our first rare disease pharmaceutical product. To the extent our ongoing and continuing efforts to commercialize this product are unsuccessful, our business, financial condition and results of operations will be negatively impacted
- 67% rewrittenRisks Related to Accounting, Tax, and SEC Rules and Regulations
We have increased exposure to tax liabilities, including foreign tax liabilities
No substantive risk change; jurisdiction names were lightly edited, including replacing “United Kingdom” with “UK”.
- 63% rewrittenRisks Related to our Business
Clinical trials for our products may not generate the outcomes we expect, may take longer or be more costly to complete than we anticipate
The risk now specifically warns that early clinical results may not predict later-stage results or outcomes in different indications.
- 62% rewrittenRisks Related to Our Industry
The continuing trend toward consolidation of customer groups could result in declines in the sales volume and prices of our products, and increased fees charged by customers, each of which could have a material adverse effect on our business, financial position, and operating results
Customer concentration shifted from four customers at 25%, 16%, 12% and 11% of revenue to three at 22%, 17% and 14%; receivables concentration fell from 70% to 64%.
- 55% rewrittenRisks Related to Our Intellectual Property
As a result of the consummation of the Merger, our reliance on third parties to manufacture and test certain of our products will increase, and if any of these third parties is unable to satisfy our demand, our business, operating results and financial condition could suffer
The wording changes from manufacturing “capability” to “capabilities” and removes “the” before quality release testing, without changing the third-party reliance.
- 49% rewrittenRisks Related to Our Intellectual Property
If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected
The confidentiality discussion adds proprietary “technology” to the protected development information; the underlying trade-secret risk is unchanged.
- 45% rewrittenRisks Related to our Business
Climate change concerns could disrupt our businesses, adversely affect client activity levels, adversely affect the creditworthiness of our counterparties, and damage our reputation
- 40% rewrittenRisks Related to our Debt
The conversion of the Notes could impair our financial position and liquidity
Was: The conversion of the Senior Notes could impair our financial position and liquidity
- 39% rewrittenRisks Related to our Debt
The accounting method for the Notes could adversely affect our reported financial condition and results
Was: The accounting method for the Senior Notes could adversely affect our reported financial condition and results
- 38% rewrittenRisks Related to Our Intellectual Property
We rely significantly on information technology and any failure, inadequacy, interruption, or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate the business effectively
- 35% rewrittenRisks Related to our Debt
Provisions in the indenture governing the Notes could delay or prevent an otherwise beneficial takeover of us
Was: Provisions in the indenture governing the Senior Notes could delay or prevent an otherwise beneficial takeover of us
- 34% rewrittenRisks Related to Our Industry
We are subject to federal, state, and local laws and regulations, and complying with these may cause us to incur significant additional costs
- 32% rewrittenRisks Related to Our Common Stock
Provisions in our charter documents and Delaware law could discourage or prevent a takeover, even if such a transaction would be beneficial to our stockholders
- 31% rewrittenRisks Related to Our Intellectual Property
Litigation or third-party claims of intellectual property infringement would require us to divert resources and may prevent or delay our commercialization of our current products or the development or regulatory approval of other product candidates
- 28% rewrittenRisks Related to our Business
We expect to spend significant resources on research and development efforts, and such efforts may not result in marketable products. Failure to successfully introduce products into the market could have a material adverse effect on our business, financial position, and operating results
Was: We expect to spend a significant amount of resources on research and development efforts, and such efforts may not result in marketable products. Failure to successfully introduce products into the market could have a material adverse effect on our business, financial position, and operating results
- 28% rewrittenRisks Related to Our Intellectual Property
Inability to protect our intellectual property in the U.S. and foreign countries could negatively affect sales of our branded products
- 27% rewrittenRisks Related to Our Common Stock
The market price of our common stock has been volatile, and an investment in our common stock could decline in value
- 26% rewrittenRisks Related to Our Industry
Public health outbreaks, epidemics, or pandemics have adversely affected and may in the future adversely affect our business
Was: Public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) have adversely affected and may in the future adversely affect our business
- 25% rewrittenRisks Related to our Debt
The capped call transactions may affect the value of the Notes and our common stock
Was: The capped call transactions may affect the value of the Senior Notes and our common stock
- 21% rewrittenRisks Related to our Business
Furthermore, if we are unable to address all regulatory requirements applicable to the development and commercialization of new products in a timely manner, our product introduction plans, business, financial position, and operating results could be materially adversely affected
- 20% rewrittenRisks Related to our Debt
Our indebtedness and liabilities could limit the cash flow available for our operations and expose us to risks that could adversely affect our business, financial condition and results of operation
All 63 risk factors
Headings as the filing states them, in filing order.
Risks Related to our Business
- 01Some of these factors are outside of our control and, if any arise, our profitability, business, financial position, and operating results could be materially adversely affected
- 02To the extent our ongoing and continuing efforts to commercialize Cortrophin Gel, ILUVIEN, and our other products for which we have received marketing approval are unsuccessful, our business, financial condition and results of operations will be negatively impacted71% rewritten
- 03We may enter into new lines of business that offer new products and/or services and we may have limited experience in marketing such new products and/or services, which may subject us to additional risks
- 04Failure to successfully manage these risks in the implementation or acquisition of new lines of business or the offering of new products or services could have a material adverse effect on our reputation, business, results of operations and financial condition71% rewritten
- 05Our manufacturing facilities or those of our third-party manufacturers or suppliers may fail to meet regulatory requirements. Failure to meet cGMP requirements could increase production costs or impact supply of our productsNew
- 06If we fail to comply with broad and complex U.S. healthcare and other laws, as well as comparable laws and regulations in foreign jurisdictions, we could face substantial penalties and our business, operations and financial condition could be adversely affectedNew
- 07The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage, and security requirements intended to prevent the unauthorized sale of pharmaceutical productsNew
- 08If we fail to comply with data protection laws and regulations, we could be subject to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity, which could negatively affect our operating results and business
- 09Furthermore, if we are unable to address all regulatory requirements applicable to the development and commercialization of new products in a timely manner, our product introduction plans, business, financial position, and operating results could be materially adversely affected21% rewritten
- 10Any failure to comply with the complex reporting and payment obligations under the Medicaid Drug Rebate Program and other government pricing and price reporting programs may result in penalties and sanctions, which may have a material adverse effect on our business, financial position, and operating resultsNew
- 11We expect to spend significant resources on research and development efforts, and such efforts may not result in marketable products. Failure to successfully introduce products into the market could have a material adverse effect on our business, financial position, and operating results28% rewritten
- 12Clinical trials for our products may not generate the outcomes we expect, may take longer or be more costly to complete than we anticipate63% rewritten
- 13Any significant adverse events or undesirable side effects caused by our products may impact regulatory approval or market acceptance, or result in significant negative consequencesNew
- 14Climate change concerns could disrupt our businesses, adversely affect client activity levels, adversely affect the creditworthiness of our counterparties, and damage our reputation45% rewritten
- 15Our current and potential future use of artificial intelligence and machine learning may not be successful and introduces emerging risks and challenges to our businessNew
Risks Related to Our Intellectual Property
- 16We may be adversely affected by the expiration of patents that protect key aspects of ILUVIEN and YUTIQ in the near- to medium-term
- 17Inability to protect our intellectual property in the U.S. and foreign countries could negatively affect sales of our branded products28% rewritten
- 18If we fail to comply with our obligations in the agreements under which we license development or commercialization rights to products or technology from third parties, we could lose license rights that are material to our business
- 19We do not control the commercialization of ILUVIEN in China, East Asia and the Western Pacific, and receipt of the value we currently anticipate will depend on, among other factors, Ocumension’s ability to further commercialize ILUVIEN in that region
- 20If we or our licensors are unable to obtain and maintain protection for the intellectual property incorporated into our products, the value of our technology and products will be adversely affected
- 21Litigation or third-party claims of intellectual property infringement would require us to divert resources and may prevent or delay our commercialization of our current products or the development or regulatory approval of other product candidates31% rewritten
- 22If our efforts to protect the proprietary nature of the intellectual property related to our products are inadequate, we may not be able to compete effectively in our markets
- 23We may become involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful
- 24If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected49% rewritten
- 25We rely significantly on information technology and any failure, inadequacy, interruption, or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate the business effectively38% rewritten
- 26We are currently involved in and may from time to time become involved in legal proceedings, some of which may result in substantial losses, government enforcement actions, damage to our business and reputation, and strain on our internal resources
- 27We are susceptible to product liability claims that may not be covered by insurance, which, if successful, could require us to pay substantial sums
- 28Our business is subject to political, economic, legal, and social risks, and if we fail to successfully manage our domestic and international operations, our business, operating results and financial condition could suffer
- 29Moreover, Alimera’s international operations rely on distributors in many countries to provide adequate levels of experience and expertise on its behalf, and we will now rely on those distributors. We need to monitor and manage these relationships appropriately to address risks in these markets
- 30As a result of the consummation of the Merger, we need to meet certain additional requirements for our international operations, including adequate levels of reimbursement and various regulatory approvals, and our inability to meet these requirements could adversely affect our results of operations
- 31As a result of the consummation of the Merger, our reliance on third parties to manufacture and test certain of our products will increase, and if any of these third parties is unable to satisfy our demand, our business, operating results and financial condition could suffer55% rewritten
- 32Future acquisitions and investments could disrupt our business and harm our financial position and operating results
Risks Related to Our Industry
- 33Public health outbreaks, epidemics, or pandemics have adversely affected and may in the future adversely affect our business26% rewritten
- 34The continuing trend toward consolidation of customer groups could result in declines in the sales volume and prices of our products, and increased fees charged by customers, each of which could have a material adverse effect on our business, financial position, and operating results62% rewritten
- 35Any prolonged disruption in the supply of imported API or increased costs due to tariffs could materially affect our ability to manufacture and distribute our products, reduce or eliminate our revenues, and have a material adverse effect on our business, financial position, and operating resultsNew
- 36We may become subject to federal and state false claims litigation brought by private individuals and the government
- 37The successful commercialization of our products depends on adequate coverage and reimbursement from third party payorsNew
- 38We are subject to federal, state, and local laws and regulations, and complying with these may cause us to incur significant additional costs34% rewritten
- 39Our operations in international markets subject us to additional regulatory oversight both in the international market and in the U.S., as well as, social, and political uncertainties, which could cause a material adverse effect on our business, financial position, and operating results
- 40U.S. healthcare reform initiatives may materially and adversely affect our business and operating resultsNew
- 41Other federal healthcare reform efforts or actions may affect access to healthcare coverage or the funding of health care benefits, although the full impact of such efforts or actions cannot be predictedNew
- 42Inflation could have a material adverse effect on our business, financial position, and operating results
Risks Related to Accounting, Tax, and SEC Rules and Regulations
- 43We have increased exposure to tax liabilities, including foreign tax liabilities67% rewritten
- 44The international nature of our operations, including those resulting from our acquisition of Alimera and its international operations, will subject us to political and economic risks and increase our exposure to potential liability under anti-corruption, trade protection, tax, and other laws and regulations
- 45The international nature of our operations (including the acquisition of Alimera) will subject us to political and economic risks that could adversely affect our business, results of operations, or financial condition
- 46Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operationsNew
- 47Failure to comply with applicable transfer pricing and similar regulations could have a material adverse effect on our financial position and operating results
- 48Changes in estimates regarding the fair value of goodwill or intangible assets may result in an adverse impact to our business, financial position, and operating results
- 49Our management is required to devote substantial time to comply with public company regulations. If we are unable to comply with these regulations, investors could lose confidence in us, which could have a material adverse effect on our stock price, business, financial position, and operating results
- 50Our policies regarding returns, allowances and chargebacks, as well as marketing programs adopted by wholesalers, may reduce revenues in future fiscal periods
Risks Related to our Debt
- 51Our indebtedness and liabilities could limit the cash flow available for our operations and expose us to risks that could adversely affect our business, financial condition and results of operation20% rewritten
- 52Our 2024 Credit Agreement contains restrictive and financial covenants and if we are not in compliance with these covenants, our outstanding indebtedness under this facility could be accelerated and the lenders could terminate their commitments under the facility
- 53Our variable rate indebtedness subjects us to interest rate risk, which could cause our debt service obligations to increase and our net income and cash flows to correspondingly decrease
- 54Shares of our common stock issuable upon conversion of the Notes may dilute the ownership interest of our common stockholders or may adversely affect the market price of our common stock74% rewritten
- 55We may be unable to raise the funds necessary to repurchase the Notes for cash following a fundamental change or to pay the cash amounts due upon maturity or conversion of the Notes, and our other indebtedness limits our ability to repurchase the Notes or to pay the cash amounts due upon their maturity or conversionNew
- 56Provisions in the indenture governing the Notes could delay or prevent an otherwise beneficial takeover of us35% rewritten
- 57The conversion of the Notes could impair our financial position and liquidity40% rewritten
- 58The accounting method for the Notes could adversely affect our reported financial condition and results39% rewritten
- 59The capped call transactions may affect the value of the Notes and our common stock25% rewritten
- 60We are subject to counterparty risk with respect to the capped call transactions, and the capped call may not operate as planned
Risks Related to Our Common Stock
- 61Raising additional funds by issuing additional equity securities may cause dilution to our current stockholders. Raising additional funds by entering into additional credit or other borrowing facilities or issuing debt may subject us to covenants and other requirements that may restrict our operations
- 62Provisions in our charter documents and Delaware law could discourage or prevent a takeover, even if such a transaction would be beneficial to our stockholders32% rewritten
- 63The market price of our common stock has been volatile, and an investment in our common stock could decline in value27% rewritten
Other Ani Pharmaceuticals 10-Ks
- FY2024 10-K risk factors62 risks
Acquisition of Alimera introduces new ophthalmic products, international operations, and third-party manufacturing dependencies.
Filed Feb 28, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.